Efficacy of N-acetylcysteine Versus Placebo as Prophylaxis of Sinusoidal Obstruction Syndrome in Patients Undergoing Hematopoietic Stem Cell Transplantation

Key facts

Sponsor

Instituto Brasileiro de Controle do Cancer

Principal Investigator

Jamilla N Cavalcante, MD

IBCC Oncologia

Intervention

N-acetylcysteine(drug)

Enrollment

80 enrolled

Eligibility

18 years · All sexes

Timeline

2021 – 2023

Study locations (1)

• Jamilla Neves Cavalcante, São Paulo, São Paulo, Brazil

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hepatic veno-occlusive disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT05987124
  Defibrotide Dose-escalation for SOS Post-HSCT
  New York Medical College
• RECRUITINGNCT06715046
  Cell Free DNA Profiling As a Tool to Monitor Clinically-Relevant Events in Allogeneic Hematopoietic Stem Cell Transplantation
  University of Turin, Italy
• RECRUITINGNCT05090345
  A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).
  Duke University
• ACTIVE NOT RECRUITINGNANCT03865589
  Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome
  Children's Mercy Hospital Kansas City

See all trials for Hepatic veno-occlusive disease →